CPC A61K 39/12 (2013.01) [A61K 9/19 (2013.01); A61K 39/39 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/36 (2013.01); A61K 47/42 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/70 (2013.01)] | 8 Claims |
1. A formulation that comprises the following components:
a) a live attenuated tetravalent dengue vaccine comprising i) about 100-10,000,000 pfu/ml rDEN1Δ30 virus, ii) about 100-10,000,000 pfu/ml rDEN2/4Δ30 virus, iii) about 100-10,000,000 pfu/ml rDEN3Δ30/31 virus, and iv) about 100-10,000,000 pfu/ml rDEN4Δ30 virus,
b) about 11 mM potassium phosphate buffer at a pH of about 7.0-8.0,
c) about 90 mg/ml sucrose,
d) about 5 mg/ml propylene glycol,
e) about 5 mg/ml sodium carboxymethylcellulose,
f) about 50 mM NaCl, and
g) about 25 mM Leu.
|